Presidio News

Presidio Gets 27 Million B-Extension for Preclinical HCV Programs.

Presidio is developing NRTIs against common reverse transcriptase mutations.

Presidio is quickly making inroads into the development of new medicines.

01.12.10
Eric Ruby Joins Presidio Pharmaceuticals, Inc. as Vice President of Regulatory Affairs

12.02.09
Tom Anderton Joins Presidio Pharmaceuticals, Inc. as Vice President of Intellectual Property and Legal Affairs

08.05.09
Dr. Nathaniel Brown Joins Presidio Pharmaceuticals, Inc. as Senior Vice President of Clinical Development

07.13.09
Presidio Pharmaceuticals, Inc. Gets $27 Million B-Extension for Preclinical HCV Programs

07.09.09
Presidio Pharmaceuticals, Inc. Raises $27 Million in Additional Financing

07.07.09
Presidio Pharmaceuticals, Inc. selects PPI-461 as a Clinical Candidate in their Hepatitis C Virus NS5A Program

04.16.09
Presidio to Present Data on HCV NS5A Inhibitor Program at EASL Conference

08.05.08
Presidio Pays Down Future XTL Milestone, Royalty, and Sublicense Payments

04.14.08
BioCentury Emerging Company Profile -  Presidio: Penultimate NRTIs

03.20.08
Presidio Obtains Rights to XTL Biopharmaceuticals' HCV NS5A Program

02.11.08
Presidio and Numerate, Inc. Announce Research Collaboration

1.07.08
Leo Redmond Joins Presidio Pharmaceuticals as Chief Financial Officer

12.05.07
Presidio Relocates Headquarters to Mission Bay, San Francisco

09.18.07
Presidio Adds Industry Veteran Colonno as Chief Scientific Officer

08.29.07
Presidio Closes $26 Million Series B Financing

07.27.07
San Francisco Business Times: Startup Takes Aim at AIDS

01.16.07
Presidio Receives Exclusive License to Novel HCV Technology from Stanford

12.20.06
Medivir Outlicenses Antivirals Alovudine (MIV-310) and MIV-410 to Presidio